1. Home
  2. SLQT vs IKT Comparison

SLQT vs IKT Comparison

Compare SLQT & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SelectQuote Inc.

SLQT

SelectQuote Inc.

N/A

Current Price

$0.81

Market Cap

204.6M

Sector

Finance

ML Signal

N/A

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

N/A

Current Price

$1.99

Market Cap

220.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SLQT
IKT
Founded
1999
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
204.6M
220.5M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
SLQT
IKT
Price
$0.81
$1.99
Analyst Decision
Hold
Strong Buy
Analyst Count
2
5
Target Price
$2.88
$5.00
AVG Volume (30 Days)
2.2M
862.5K
Earning Date
05-05-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
105.00
57.76
EPS
0.11
N/A
Revenue
$1,526,594,000.00
N/A
Revenue This Year
$10.97
N/A
Revenue Next Year
$6.14
N/A
P/E Ratio
$7.19
N/A
Revenue Growth
15.50
N/A
52 Week Low
$0.56
$1.33
52 Week High
$2.77
$2.26

Technical Indicators

Market Signals
Indicator
SLQT
IKT
Relative Strength Index (RSI) 41.28 67.39
Support Level $0.79 $1.63
Resistance Level $0.94 $2.13
Average True Range (ATR) 0.10 0.09
MACD -0.01 0.03
Stochastic Oscillator 4.92 78.62

Price Performance

Historical Comparison
SLQT
IKT

About SLQT SelectQuote Inc.

SelectQuote Inc is a Direct-to-consumer (DTC) distribution platform which facilitates consumers to shop for health, life and auto & home insurance policies online. The company generates its revenues by selling insurance products on behalf of the insurance carrier partners in the form of a commission. It has four reportable segments namely Senior, Healthcare Services, Life, and Auto & Home. It functions through three lines namely, SelectQuote Senior, SelectQuote Life, and SelectQuote Auto & Home.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

Share on Social Networks: